Simplify Logo

Full-Time

Procurement Manager

Posted on 6/27/2024

Arcellx

Arcellx

51-200 employees

Develops cell therapies for cancer, autoimmune diseases

Hardware
Biotechnology

Mid, Senior

North Bethesda, MD, USA

Category
Procurement & Sourcing
Operations & Logistics
Required Skills
Communications
Management
Requirements
  • 3+ years’ relevant experience in pharma/biotech purchasing and/or sourcing
  • Demonstrated ability to execute at a high-level on the main tasks of the role, including vendor management and negotiation, using an ERP system (NetSuite is a plus), inventory controls and material movement, etc.
  • Must be able to work independently in a fast-paced startup environment
  • Exceptional communication and interpersonal skills
  • Ability to work in a lab setting/environment and handle materials up to 50lbs.
Responsibilities
  • Oversee Procurement Operations
  • Supplier Management
  • Purchase Order Management
  • Strategic Procurement & Insights
  • Stakeholder Collaboration
  • Contract & Sourcing
  • Policy & Training Development

Arcellx develops innovative cell therapies for cancer and autoimmune diseases, leveraging their novel D-Domain technology and transformative ddCAR and ARC-SparX platforms to enhance cell therapy.

Company Stage

N/A

Total Funding

$736M

Headquarters

Gaithersburg, Maryland

Founded

2014

Growth & Insights
Headcount

6 month growth

16%

1 year growth

25%

2 year growth

76%
Simplify Jobs

Simplify's Take

What believers are saying

  • The Phase 3 iMMagine-3 trial for anito-cel could significantly boost Arcellx's market position if successful.
  • Recent robust long-term responses from the Phase 1 expansion trial of anito-cel indicate promising efficacy and safety, potentially leading to FDA approval.
  • The $285M equity investment and upfront cash from Kite provide substantial financial backing for Arcellx's ongoing and future projects.

What critics are saying

  • The competitive landscape for CAR T therapies is intense, with established players like Abecma and Carvykti posing significant challenges.
  • Regulatory hurdles, such as the recent FDA partial hold, could delay product development and market entry.

What makes Arcellx unique

  • Arcellx's anitocabtagene autoleucel (anito-cel) is the first BCMA CAR T therapy for multiple myeloma utilizing a novel D-Domain binder, setting it apart from existing treatments.
  • The company's strategic partnership with Kite, a Gilead Company, enhances its research capabilities and market reach, distinguishing it from smaller biotech firms.
  • Arcellx's focus on innovative immunotherapies for cancer and other incurable diseases positions it uniquely in the biotech landscape.
INACTIVE